Lacosamide - Revision history

Danbot: Remove refs with incorrect PMIDs (verified against PubMed)

2026-03-22T10:26:49Z

Remove refs with incorrect PMIDs (verified against PubMed)

← Older revision		Revision as of 10:26, 22 March 2026
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Anticonvulsant]]~~<ref>Beydoun A, et al. Lacosamide: pharmacology, mechanisms of action. Expert Rev Neurother. 2009;9(1):33-42. PMID 19102667</ref>~~		*Type: [[Anticonvulsant]]
	*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV		*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV
	*Common Trade Names: Vimpat		*Common Trade Names: Vimpat

Danbot: Add peer-reviewed reference

2026-03-22T10:09:09Z

Add peer-reviewed reference

← Older revision		Revision as of 10:09, 22 March 2026
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Anticonvulsant]]		*Type: [[Anticonvulsant]]<ref>Beydoun A, et al. Lacosamide: pharmacology, mechanisms of action. Expert Rev Neurother. 2009;9(1):33-42. PMID 19102667</ref>
	*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV		*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV
	*Common Trade Names: Vimpat		*Common Trade Names: Vimpat

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:25Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:58, 20 March 2026
Line 89:		Line 89:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Add MedicationDose SMW query table for dynamic indications by condition

2026-03-20T20:36:42Z

Add MedicationDose SMW query table for dynamic indications by condition

@@ Line 79: / Line 79: @@
 *Excretion: urine 95% (40% unchanged), feces <0.5%
 *Mechanism of Action: exact mechanism unknown; enhances slow inactivation of voltage-sensitive Na channels, stabilizing neuronal membranes, inhibiting repetitive firing
 ==See Also==

Elcatracho: /* See Also */

2021-03-08T15:44:23Z

ClaireLewis at 22:49, 22 September 2019

2019-09-22T22:49:45Z

← Older revision		Revision as of 22:49, 22 September 2019
Line 1:		Line 1:
	==General==		==General==
	*Type: Anticonvulsant		*Type: [[Anticonvulsant]]
	*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV		*Dosage Forms: 50, 100, 150, 200 PO/IV; 10/mL sol IV
	*Common Trade Names: Vimpat		*Common Trade Names: Vimpat
Line 86:		Line 86:
	epocrates, medscape		epocrates, medscape

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Neurology]]

Rossdonaldson1: Text replacement - "Diarrhea" to "Diarrhea"

2016-09-24T17:48:56Z

Text replacement - "*Diarrhea" to "*Diarrhea"

← Older revision		Revision as of 17:48, 24 September 2016
Line 66:		Line 66:
	**Nystagmus (5%)		**Nystagmus (5%)
	**Balance disorder (4%)		**Balance disorder (4%)
	**Diarrhea (4%)		**[[Diarrhea]] (4%)
	**Injection site discomfort (2.5%)		**Injection site discomfort (2.5%)
	**Depression (2%)		**Depression (2%)

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-25T04:05:31Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 04:05, 25 July 2016
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	*Monotherapy		*Monotherapy
	**~~100 mg~~ PO/IV q12hr initially, THEN, based on response and tolerability, increase dose at weekly intervals by ~~50 mg~~ PO/IV BID; up to a recommended dose of 150-~~200 mg~~ BID		**100mg PO/IV q12hr initially, THEN, based on response and tolerability, increase dose at weekly intervals by 50mg PO/IV BID; up to a recommended dose of 150-200mg BID
	**Alternate loading dose schedule: ~~200 mg~~ PO/IV as a single dose, followed ~12 hr later by starting ~~100 mg~~ PO/IV BID x 1 week, THEN increase dose at weekly intervals by ~~50 mg~~ BID; up to a recommended dose of 150-~~200 mg~~ BID		**Alternate loading dose schedule: 200mg PO/IV as a single dose, followed ~12 hr later by starting 100mg PO/IV BID x 1 week, THEN increase dose at weekly intervals by 50mg BID; up to a recommended dose of 150-200mg BID
	**In patients already taking an antiepileptic drug (AED), maintain lacosamide at recommended maintenance dose of 150-~~200 mg~~ PO BID for at least 3 days before initiating withdrawal of the previous AED		**In patients already taking an antiepileptic drug (AED), maintain lacosamide at recommended maintenance dose of 150-200mg PO BID for at least 3 days before initiating withdrawal of the previous AED
	*Adjunctive therapy		*Adjunctive therapy
	**Initial: ~~50 mg~~ PO/IV q12hr		**Initial: 50mg PO/IV q12hr
	**Based on response and tolerability, increase dose at weekly intervals by ~~50 mg~~ PO/IV BID; up to a recommended dose of 100-~~200 mg~~ BID		**Based on response and tolerability, increase dose at weekly intervals by 50mg PO/IV BID; up to a recommended dose of 100-200mg BID
	*Max ~~400 mg~~/day		*Max 400mg/day

	==Pediatric Dosing==		==Pediatric Dosing==
Line 22:		Line 22:
	*Lactation: saftey unknown		*Lactation: saftey unknown
	*Renal Dosing		*Renal Dosing
	**Severe (CrCl <30 mL/min): Not to exceed ~~300 mg~~/day		**Severe (CrCl <30 mL/min): Not to exceed 300mg/day
	**Hemodialysis: Supplement with up to 50% of dose after dialysis		**Hemodialysis: Supplement with up to 50% of dose after dialysis
	*Hepatic Dosing		*Hepatic Dosing
	**Mild to moderate: Not to exceed ~~300 mg~~/day		**Mild to moderate: Not to exceed 300mg/day
	**Severe: Not recommended		**Severe: Not recommended

Neil.m.young: Text replacement - " w/ " to " with "

2016-07-12T07:58:31Z

Text replacement - " w/ " to " with "

← Older revision		Revision as of 07:58, 12 July 2016
Line 47:		Line 47:
	*Syncope		*Syncope
	*Suicidality		*Suicidality
	*Drug Rash w/ eosinophilia and systemic sx		*Drug Rash with eosinophilia and systemic sx
	*Stevens-Johnson		*Stevens-Johnson
	*Toxic epidermal necrolysis		*Toxic epidermal necrolysis

Neil.m.young: Text replacement - "==Sources==" to "==References=="

2016-06-26T14:01:12Z

Text replacement - "==Sources==" to "==References=="

← Older revision		Revision as of 14:01, 26 June 2016
Line 83:		Line 83:
	[[Anticonvulsants]]		[[Anticonvulsants]]

	==~~Sources~~==		==References==
	epocrates, medscape		epocrates, medscape

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

← Older revision		Revision as of 15:44, 8 March 2021
Line 81:		Line 81:

	==See Also==		==See Also==
	[[Anticonvulsants]]		*[[Seizure]]
			*[[Anticonvulsants]]
			*[[Anticonvulsant levels and reloading]]

	==References==		==References==